Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide for slowing progression in ADPKD
NL-OMON39497Phase 3Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jul 2012
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lanreotide in autosomal dominant polycystic kidney disease (ADPKD) and Polycystic liver disease (PLD) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Change in renal function. Started Jul 2012; status: active, not recruiting.
02
Drugs
lanreotide
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)Polycystic liver disease (PLD)
Beyond the preview
Go deeper on NL-OMON39497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39497.